A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes.,European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes.
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2019-12-21 , DOI: 10.1002/ejhf.1656
Anders Hostrup Larsen ₁ , Niels Jessen _{2,

3,

4} , Helene Nørrelund ₅ , Lars Poulsen Tolbod ₆ , Hendrik Johannes Harms ₆ , Søren Feddersen ₇ , Flemming Nielsen ₇ , Kim Brøsen ₇ , Nils Henrik Hansson ₁ , Jørgen Frøkiaer ₆ , Steen Hvitfeldt Poulsen ₁ , Jens Sörensen _{6,

8} , Henrik Wiggers ₁

Affiliation

The present study tested the hypothesis that metformin treatment may increase myocardial efficiency (stroke work/myocardial oxygen consumption) in insulin‐resistant patients with heart failure and reduced ejection fraction (HFrEF) without diabetes.

中文翻译：